Literature DB >> 1672862

DuP 753 is a specific antagonist for the angiotensin receptor.

N E Rhaleb1, N Rouissi, F Nantel, P D'Orléans-Juste, D Regoli.   

Abstract

2-n-Butyl-4-chloro-5-hydroxy-methyl-1-[(2'-(1H)-tetrazol-5-yl)biph enyl-4- yl)methyl]imidazol potassium salt (DuP 753) is a nonpeptide angiotensin II receptor antagonist that inhibits the contractile effects of angiotensin II competitively and shows pA2 values of 8.27 on the rabbit aorta and jugular vein, 8.66 on the rat portal vein and stomach, 8.19 on the rat urinary bladder, and 8.36 on human colon, ileum, and urinary bladder. This agent (more than 10(-5) M) exhibits no agonistic activity and does not affect the contractile effects of norepinephrine, acetylcholine, bradykinin, desArg9-bradykinin, substance P, neurokinin A, neurokinin B, or bombesin in the various tissues. The present results demonstrate that DuP 753 is a potent nonpeptide antagonist with high affinity, specificity, and selectivity for the angiotensin receptor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672862     DOI: 10.1161/01.hyp.17.4.480

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  11 in total

Review 1.  ACE inhibitors and proteinuria.

Authors:  R T Gansevoort; D de Zeeuw; P E de Jong
Journal:  Pharm World Sci       Date:  1996-12

2.  Angiotensin II receptors involved in the enhancement of noradrenergic transmission in the caudal artery of the spontaneously hypertensive rat.

Authors:  S L Cox; D F Story; J Ziogas
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

3.  Effects of angiotensin II antagonists on the contractile and hydrosmotic effect of AT II and AT III in the toad (Bufo arenarum).

Authors:  M Peral de Bruno; A Coviello
Journal:  J Comp Physiol B       Date:  1996       Impact factor: 2.200

Review 4.  Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients?

Authors:  F D Hobbs
Journal:  Br J Gen Pract       Date:  2000-09       Impact factor: 5.386

Review 5.  Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.

Authors:  K L Goa; A J Wagstaff
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

6.  Should ACE inhibitors and ARBs be used in combination in children?

Authors:  Brian R Stotter; Michael A Ferguson
Journal:  Pediatr Nephrol       Date:  2018-08-15       Impact factor: 3.714

7.  Action of AT1 receptor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries.

Authors:  R S Garcha; P S Sever; A D Hughes
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

8.  Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.

Authors:  R A Lafayette; G Mayer; S K Park; T W Meyer
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

9.  Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.

Authors:  M J Robertson; J C Barnes; G M Drew; K L Clark; F H Marshall; A Michel; D Middlemiss; B C Ross; D Scopes; M D Dowle
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

10.  Evidence for the involvement of different receptor subtypes in the pre- and postjunctional actions of angiotensin II at rat sympathetic neuroeffector sites.

Authors:  S L Cox; A Ben; D F Story; J Ziogas
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.